PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug
that are known to target specific cells (in this case, cells in the immune system) The DC RCC
Vaccine is agent that tries to help the immune system to recognize and fight against cancer
cells.
The purpose of this research study is to determine the safety of CT-011 alone, and in
combination with the Dendritic Cell Renal Cell Carcinoma (DC RCC) vaccine. The investigators
are also trying to find out what effect the combination has on the disease, and on your
immune system.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)